Hyman B. Muss, MD, UNC Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses adjuvant therapy for elderly patients with HER2-positive or triple negative breast cancer (TNBC).

Hyman B. Muss, MD, UNC Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses adjuvant therapy for elderly patients with HER2-positive or triple negative breast cancer (TNBC).

Related Content

Significant Delay in CNS Progression Achieved With Tucatinib Triplet in HER2+ Metastatic Breast Cancer

May 29, 2020 09:30pm

By Lisa Astor

Alpelisib Generates Promising Responses in PI3KCA+ Breast Cancer After Progression on CDK Inhibitor

May 29, 2020 07:30pm

By Jason Broderick

Overall Survival Not Increased With Locoregional Therapy in Advanced Breast Cancer

May 28, 2020 11:00pm

By Jason Harris

The TBCRC049 Trial for Treating Leptomeningeal Metastases in HER2+ Breast Cancer

December 14, 2019 06:00am

By Adam M. Brufsky, MD, PhD, FACP